3D細胞培養市場－全球產業規模、佔有率、趨勢、機會及預測（依技術、應用、最終用途、地區及競爭格局分類，2021-2031年）

全球 3D 細胞培養市場預計將從 2025 年的 117.8 億美元成長到 2031 年的 186.4 億美元，複合年成長率為 7.95%。

該市場涵蓋了能夠使細胞在3D環境中生長的技術，這種環境比標準的單層培養技術更能精確地模擬體內環境。其成長主要受以下因素驅動：藥物研發領域對動物模型替代測試方法的需求日益成長，以及對個人化醫療的日益重視。此外，慢性疾病的增加也催生了再生醫學和腫瘤學領域對可靠疾病模型的需求。例如，美國癌症協會預測，到2024年，美國將新增2,001,140例癌症病例，這將推動業界對精準的體外腫瘤模型的需求，以加速治療方法的研發。

儘管成長勢頭強勁，但由於各種3D培養平台缺乏標準化和可重複性，市場仍面臨許多挑戰。建構均一​​的支架基質和維持一致的微環境涉及許多複雜環節，往往導致實驗數據出現差異，並使監管核准所需的檢驗步驟更加複雜。因此，實施這些複雜系統的高昂成本以及對專業技術知識的需求，仍然是限制其在小規模實驗室和商業機構中廣泛應用的重要障礙。

市場促進因素

藥物研發中3D細胞培養模型的廣泛應用，其根本驅動力在於倫理和監管方面的迫切需求，即以更具預測性和更貼近人體實際情況的系統取代動物實驗。藥物研發人員正優先考慮生理上精確的人源類器官，以更好地預測藥物的毒性和療效，從而摒棄傳統的單層細胞培養方法，因為後者往往無法重現複雜的生物反應。聯邦政府大力推動新型方法的標準化，使其適用於工業應用，也為此趨勢提供了支持。值得注意的是，Fierce Biotech在2025年9月報道稱，美國國立衛生研究院（NIH）已授予一項價值8700萬美元的契約，用於建立一個“標準化類器官建模中心”，旨在減少轉化科學中對動物模型的依賴。這種高水準的支持將透過最大限度地降低物種間差異帶來的風險，促進3D平台的商業性化應用。

與監管政策的調整同步，微流體和生物列印等先進技術的進步，使得建構複雜的功能性組織系統成為可能，並推動市場發展。器官晶片介面和血管化技術的創新，有助於解決厚組織構建體中營養輸送的難題，並吸引了大量研發資金。例如，2025年10月，博伊西州立大學新聞報道稱，研究人員獲得了200萬美元的津貼，用於開發適用於3D生物列印組織的可適應、軟性電子界面，以推進“類器官智慧”的發展，這凸顯了工程學和生物學的融合。鑑於藥物研發涉及巨大的財務風險，這種技術成熟至關重要。 BioSpace在2025年5月指出，2024年全球藥物研發支出將達到約2,880億美元，增加了開發高效3D培養工具的壓力，以將這些巨額投資轉化為治療成果。

市場挑戰

不同3D細胞培養平台缺乏標準化和可重複性，嚴重阻礙了全球3D細胞培養市場的成長。由於這些系統通常依賴複雜的微環境和精密的支架基質，不同實驗室甚至不同批次的實驗數據可能有顯著差異。這種不一致增加了監管機構檢驗流程的難度，因為監管機構需要嚴格且可重複的證據來確保新型療法的安全性。因此，製藥公司往往不願意將這些技術全面整合到其關鍵的藥物開發平臺中，擔心數據差異會導致代價高昂的延誤和監管部門的拒絕。

由於性能和可靠性方面存在不確定性，業界採取了謹慎的態度，導致商業性化應用速度放緩。此類整合相關的財務風險龐大，進一步阻礙了非標準化工具的使用。根據美國藥品研究與製造商協會 (PhRMA) 2024 年的報告，其成員公司在過去十年中已在研發活動方面投入超過 8,500 億美元。鑑於如此龐大的投資，業界需要能夠確保結果一致性的調查方法，而目前缺乏標準化是市場擴張的直接障礙。

市場趨勢

高通量篩檢自動化技術的整合正在迅速改變市場格局，它消除了傳統上複雜3D模型維護所需的大量人工環節。自動化液體處理和培養系統能夠精確控制精細的球狀體和類器官的工作流程，從而在不影響細胞活性的前提下實現生理檢測的規模化。這種操作方式的轉變對於3D生物學的產業化至關重要，它以標準化的通訊協定操作流程取代了人工干預，確保了實驗的一致性。這些效率的提升意義重大：根據Molecular Devices公司（2025年8月）報道，其推出的專用搖床培養技術將腦類器官培養所需的人工操作時間減少了90%，顯著加快了神經退化性疾病研究的進程。

同時，人工智慧與3D影像分析的融合對於解讀多細胞模型產生的龐大且複雜的資料集至關重要。先進的機器學習演算法正被應用於解讀晶片器官和組織構建體中複雜的形態模式，並識別傳統分析方法無法檢測到的細微表現型​​反應。計算智慧與人性化的生物學之間的這種協同作用，正顯著推動資本流向能夠更準確預測臨床結果的平台。這一趨勢在2025年1月尤為明顯，當時Valo Health宣布擴大與諾和諾德的合作。這項旨在利用人工智慧驅動的人體組織模型發現新型療法的合作，涉及高達46億美元的里程碑付款。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球3D細胞培養市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依技術分類（基於支架的、無支架的、生物反應器、微流體、生物列印）
  • 按應用領域（癌症研究、幹細胞研究/組織工程、藥物開發/毒性測試）
  • 依最終用戶（生技/製藥公司、學術/研究機構、醫院、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美3D細胞培養市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲3D細胞培養市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區3D細胞培養市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲3D細胞培養市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲3D細胞培養市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球3D細胞培養市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Tecan Trading AG
• Merck KGaA
• Promocell GmbH
• Lonza Group
• Tecan Trading AG
• CN Bio Innovations Ltd.
• TissUse GmbH
• Cellendes GmbH
• Greiner Bio-one International GmbH
• Advanced BioMatrix, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global 3D Cell Culture Market is projected to expand from USD 11.78 Billion in 2025 to USD 18.64 Billion by 2031, exhibiting a CAGR of 7.95%. This market encompasses technologies that enable cells to proliferate in a three-dimensional setting, mimicking natural in vivo conditions more accurately than standard monolayer techniques. Growth is primarily fuelled by the rising demand for alternative testing methods to supersede animal models in pharmaceutical research and an increasing emphasis on personalized medicine. Furthermore, the growing prevalence of chronic diseases requires robust disease modeling for regenerative medicine and oncology; for instance, the American Cancer Society projected 2,001,140 new cancer cases in the United States in 2024, intensifying the industrial need for precise in vitro oncology models to expedite therapeutic development.

Despite this positive growth trajectory, the market encounters significant obstacles regarding the lack of standardization and reproducibility across various 3D culture platforms. The complexity involved in creating uniform scaffold matrices and sustaining consistent microenvironments often results in variable experimental data, complicating the validation steps necessary for regulatory approval. Consequently, the substantial costs linked to deploying these intricate systems, coupled with the need for specialized technical expertise, continue to act as major barriers that limit widespread adoption within smaller research laboratories and commercial organizations.

Market Driver

The increasing utilization of 3D cell culture models in drug discovery is fundamentally driven by urgent ethical and regulatory mandates to replace animal testing with more predictive, human-relevant systems. Pharmaceutical developers are prioritising physiologically accurate human-derived organoids to improve the prediction of toxicity and efficacy, shifting away from conventional monolayer cultures that often fail to replicate complex biological responses. This movement is bolstered by significant federal efforts to standardize these new methods for industry use; notably, Fierce Biotech reported in September 2025 that the NIH awarded $87 million in contracts to establish the Standardized Organoid Modeling Center, specifically aiming to reduce reliance on animal models in translational science. Such high-level endorsement promotes broader commercial adoption of 3D platforms to minimize risks linked to interspecies variability.

Parallel to regulatory shifts, the market is propelled by sophisticated technological advancements in microfluidics and bioprinting that facilitate the creation of complex, functional tissue systems. Innovations in organ-on-chip interfaces and vascularization are resolving previous limitations regarding nutrient delivery in thick tissue constructs, thereby attracting substantial developmental capital. For example, Boise State News reported in October 2025 that researchers received a $2 million grant to advance "organoid intelligence" by developing flexible electronic interfaces adaptable to 3D bioprinted tissues, highlighting the convergence of engineering and biology. This technical maturation is critical given the immense financial stakes in drug development; BioSpace noted in May 2025 that global pharmaceutical R&D spending reached nearly $288 billion in 2024, increasing the pressure to adopt efficient 3D culture tools that ensure these vast investments yield successful therapeutic outcomes.

Market Challenge

The absence of standardization and reproducibility across varying 3D culture platforms constitutes a significant barrier hampering the growth of the Global 3D Cell Culture Market. Because these systems often rely on intricate microenvironments and complex scaffold matrices, experimental data can fluctuate substantially between different laboratories or even production batches. This inconsistency complicates the validation process required by regulatory bodies, which mandate rigorous and reproducible evidence to ensure the safety of new therapeutics. Consequently, pharmaceutical companies often hesitate to fully integrate these technologies into their critical drug development pipelines, fearing that data variability could lead to costly delays or regulatory rejections.

This uncertainty regarding performance and reliability forces the industry to maintain a cautious approach, thereby slowing widespread commercial adoption. The financial stakes associated with such integration are massive, further discouraging the use of non-standardized tools. According to the Pharmaceutical Research and Manufacturers of America, in 2024, it was reported that member companies had invested over $850 billion in research and development activities over the past decade. Given this immense level of capital commitment, the industry requires testing methodologies that guarantee uniform results, making the current lack of standardization a direct impediment to market expansion.

Market Trends

The integration of High-Throughput Screening Automation is rapidly transforming the market by resolving the bottleneck of labor-intensive maintenance traditionally required for complex 3D models. Automated liquid handling and incubation systems are now capable of managing the delicate workflows of spheroids and organoids with precision, enabling laboratories to scale physiological assays without compromising viability. This operational shift is critical for industrializing 3D biology, as it replaces manual interventions with standardized robotic protocols that ensure experimental consistency. The impact of these efficiencies is profound; according to Molecular Devices, August 2025, the introduction of their specialized rocking incubation technology has reduced the hands-on time required for maintaining brain organoid cultures by 90%, significantly accelerating the timeline for neurodegenerative disease research.

Simultaneously, the Convergence of Artificial Intelligence with 3D Image Analysis is becoming essential for interpreting the massive, complex datasets generated by multi-cellular models. Advanced machine learning algorithms are now deployed to deconvolute intricate morphological patterns within organ-on-chip and tissue constructs, identifying subtle phenotypic responses that traditional analysis methods fail to detect. This synergy between computational intelligence and human-centric biology is driving substantial capital allocation toward platforms that can predict clinical outcomes more accurately. This trend was exemplified when Valo Health, January 2025, announced an expanded collaboration with Novo Nordisk to discover novel therapeutics using AI-driven human tissue models, a partnership valued at up to $4.6 billion in potential milestone payments.

Key Market Players

• Tecan Trading AG
• Merck KGaA
• Promocell GmbH
• Lonza Group
• Tecan Trading AG
• CN Bio Innovations Ltd.
• TissUse GmbH
• Cellendes GmbH
• Greiner Bio-one International GmbH
• Advanced BioMatrix, Inc.

Report Scope

In this report, the Global 3d Cell Culture Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

3d Cell Culture Market, By Technology

• Scaffold Based
• Scaffold Free
• Bioreactors
• Microfluidic
• Bioprinting

3d Cell Culture Market, By Application

• Cancer Research
• Stem Cell Research & Tissue Engineering
• Drug Development & Toxicity Testing

3d Cell Culture Market, By End-Use

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes
• Hospitals
• Others

3d Cell Culture Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global 3d Cell Culture Market.

Available Customizations:

Global 3d Cell Culture Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global 3d Cell Culture Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Scaffold Based, Scaffold Free, Bioreactors, Microfluidic, Bioprinting)
  • 5.2.2. By Application (Cancer Research, Stem Cell Research & Tissue Engineering, Drug Development & Toxicity Testing)
  • 5.2.3. By End-Use (Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, Hospitals, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America 3d Cell Culture Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By End-Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States 3d Cell Culture Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-Use
  • 6.3.2. Canada 3d Cell Culture Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-Use
  • 6.3.3. Mexico 3d Cell Culture Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-Use

7. Europe 3d Cell Culture Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By End-Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany 3d Cell Culture Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-Use
  • 7.3.2. France 3d Cell Culture Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-Use
  • 7.3.3. United Kingdom 3d Cell Culture Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-Use
  • 7.3.4. Italy 3d Cell Culture Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-Use
  • 7.3.5. Spain 3d Cell Culture Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-Use

8. Asia Pacific 3d Cell Culture Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By End-Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China 3d Cell Culture Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-Use
  • 8.3.2. India 3d Cell Culture Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-Use
  • 8.3.3. Japan 3d Cell Culture Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-Use
  • 8.3.4. South Korea 3d Cell Culture Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-Use
  • 8.3.5. Australia 3d Cell Culture Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-Use

9. Middle East & Africa 3d Cell Culture Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By End-Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia 3d Cell Culture Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-Use
  • 9.3.2. UAE 3d Cell Culture Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-Use
  • 9.3.3. South Africa 3d Cell Culture Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-Use

10. South America 3d Cell Culture Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By End-Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil 3d Cell Culture Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-Use
  • 10.3.2. Colombia 3d Cell Culture Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-Use
  • 10.3.3. Argentina 3d Cell Culture Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global 3d Cell Culture Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Tecan Trading AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Promocell GmbH
• 15.4. Lonza Group
• 15.5. Tecan Trading AG
• 15.6. CN Bio Innovations Ltd.
• 15.7. TissUse GmbH
• 15.8. Cellendes GmbH
• 15.9. Greiner Bio-one International GmbH
• 15.10. Advanced BioMatrix, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer